Seeing further.


We’re advancing our RNA-based treatments so patients with cancer can enjoy the moments that matter.

Learn More

Transforming Immunity. Restoring Hope.

We’re committed to redefining the treatment of certain cancers and rare diseases.

Learn More

Scientists. Believers. People.

At Idera, we’re working hard to translate our nucleic acid science into life-changing medicines.

Discover Idera

The Latest

Keep up with what’s happening at Idera Pharmaceuticals.


Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

– Completed Enrollment in ILLUMINATE-301; Top-Line Overall Response Rate (ORR) Data Expected in… Read more 

Idera Pharmaceuticals Completes Enrollment in ILLUMINATE-301, its Registrational Trial of Tilsotolimod in Combination with Ipilimumab in Patients with Anti-PD-1 Refractory Advanced Melanoma

Overall Response Rate (ORR) Data Anticipated Q1 2021 EXTON, Pa. , March 05, 2020 (GLOBE NEWSWIRE)… Read more 

Idera Pharmaceuticals Provides 2020 Update and Outlook

Company to Present at the 38th Annual J.P. Morgan Healthcare Conference on Thursday, January 16,… Read more 

Learn More


Idera Pharmaceuticals, Inc. Events

Idera Pharmaceuticals, Inc. Events… Read more 

Learn More